February, 2021

Bruker Pharma News

Biologics and Biosimilars

From R&D to Point of Care

On-demand 30 min talk: Curious about where we are with biologics and biosimilars analysis? Listen to Anna Codina, Bruker BioSpin, for an update on high order structure, impurity profiling, polysorbates raw material testing and contactless weight check of vials and syringes!

Comprehensive Assessment of Protein and Excipient Stability in BioPharmaceutical Formulations

Simultaneous small molecule and protein (mAb) force degradation studies by 1D 1H NMR, without the need of sample manipulation. Congratulations to Alexander Golovanov and Jack Bramham, The University of Manchester, and Adrian Podmore and Stephanie A. Davies, AstraZeneca!

New Benchtop TD-NMR Solutions for Pharma and BioPharma

On-demand flash webinar: Matteo Pennestri, Bruker BioSpin, is showing proof of concept for aggregation testing of biologics; fill check results from a study in collaboration with a pharmaceutical company and form check quantification under GxP.

Michael Greig discusses CCS and Benefits of TIMS

Become CCS-Aware! The benefits of Trapped Ion Mobility Spectrometry (TIMS) and Collisional Cross Section (CCS) for Molecular Characterization in Drug Discovery and Development. Michael Greig, Dir. Pharma/Biopharma Americas, Bruker Daltonics, discusses CCS and Benefits of TIMS.